[29 April 2013]
Products Affected - Description
Calcium Disodium Versenate, Medicis
200 mg/mL, 2.5 mL ampules (NDC 29336-0400-10)
200 mg/mL, 2.5 mL ampules (NDC 29336-0510-10)
Reason for the Shortage
- Graceway Pharmaceuticals was purchased by Medicis in December, 2011. Medicis became a division of Valeant as of March 1, 2013, and the company has resumed manufacturing of calcium disodium versenate.
- FDA has allowed extended expiry on one lot of current available product. The 2.5 mL ampules (NDC 29336-0400-10, Lot #0503) have a labeled expiry of June 30, 2015.
No products are currently available.
Estimated Resupply Dates
Medicis has a limited supply of calcium disodium versenate available for hospitals only by direct order or drop shipment.
April 29, 2013; March 7, 2013; January 14, 2013; October 15, 2012; August 8, 2012; June 27, 2012; May 16, 2012; March 9, 2012; February 13, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins